OncoMatch/Clinical Trials/NCT03658785
Immunotherapy for the Treatment of Advanced Solid Tumor
Is NCT03658785 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including TIL and Aldesleukin for recurrence tumor.
Treatment: TIL · Aldesleukin · Cyclophosphamide · Fludarabine — The purpose of this study is to evaluate the safety, side effects and benefits of autologous tumor infiltrating lymphocytes (TIL) specific to personalized Neo-antigens in the treatment of patients with recurrent, metastatic and advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: any prior therapy directed at the malignant tumor
Patients must have progressive disease while receiving or after the completion of the most recent prior treatment
Cannot have received: organ allograft
Patients who have received an organ allograft
Cannot have received: prior cell transfer therapy
Patients who have received...prior cell transfer therapy
Lab requirements
Blood counts
ANC > 1000/mm³ without filgrastim; WBC ≥ 3000/mm³; platelets ≥ 100,000/mm³; hemoglobin > 8.0 g/dl
Kidney function
Serum creatinine ≤ 1.6 mg/dl
Liver function
Serum ALT/AST ≤ 2.5x ULN; total bilirubin ≤ 1.5 mg/dl (≤ 3.0 mg/dl for Gilbert's Syndrome)
Cardiac function
LVEF ≥ 45%; NYHA Class < 2
Hematology: ANC > 1000/mm(3) without filgrastim; WBC ≥ 3000/mm(3); Platelet count ≥ 100,000/mm(3); Hemoglobin > 8.0 g/dl. Chemistry: ALT/AST ≤ 2.5x ULN; creatinine ≤ 1.6 mg/dl; total bilirubin ≤ 1.5 mg/dl (≤ 3.0 mg/dl for Gilbert's Syndrome). Cardiac: LVEF < 45% or NYHA Class 2 or higher [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03658785 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior organ allograft, prior cell transfer therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify